Search

Highlights from the SWG

SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)

Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).

Read more

SWG Educational Activities

Social and public activitiesSince 2020, Prof Hermann Einsele has been a Councilor to the EHA Board. Scientific activitiesFifth European CAR T-cell meetingDateFebruary 9–11, 2023. LocationRotterdam, The Netherlands.

Read more

European Scientific foundation for Laboratory Hemato Oncology (ESLHO)

The objectives of ESLHO are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies, as well as to facilitate quality control and education in this field.

Read more

Publications

The publications of the ESLHO networks can be found on the following pages:

EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.

Read more

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Highlights from the SWG

EHA2023 CongressThe EHA2023 Congress was held in Frankfurt, Germany, in June 2023. Guideline sessionTitle‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias.

Read more

Abstract Presentation Information

Thank you for submitting your abstract to the EHA-SfPM Precision Medicine Meeting, to be held on September 25-27, 2024 in Copenhagen, Denmark.

Read more

Highlights of the EHA-EMA Joint Symposium on RWE

The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.

Read more